Estrogen blockage reduces risk of dying from lung cancer
Geneva – Anti-estrogens such as Tamixofen can reduce the risk of dying from lung cancer by 87%, researchers from Swiss Cancer Registry report in Cancer, the journal of the American Cancer Society. "Our results support the hypothesis that there is a hormonal influence on lung cancer which has been suggested by findings such as the presence of estrogen and progesterone receptors in a substantial proportion of lung cancers," said lead investigator Dr. Rapiti. Analysing data from studies with breast cancer patients, who developed lung cancer, Rapiti found that patients, who received Tamixofen treatment, had a 87% lower risk of death than the general population (Cancer, DOI: 10.1002/cncr.25638).
Previous research suggests that menopausal hormone therapy increases women's risk of dying from lung cancer. "If prospective studies confirm our results and find that anti-estrogen agents improve lung cancer outcomes, this could have substantial implications for clinical practice," Rapiti said.